checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA has a proven safety and tolerability profile1

The long-term safety profile of OTEZLA was generally similar to that observed in clinical trials1

 

THE INCIDENCE OF MOST ADVERSE REACTIONS DID NOT INCREASE WITH LONGER-TERM USE1

adverse reactions did not increase with longer term use of otezla
  • Nausea and diarrhea were generally mild to moderate in severity, occurred during the first
    2 weeks of treatment, and generally resolved in the first month with continued treatment
  • Most adverse reactions were mild to moderate in severity across all 3 years of
    OTEZLA treatment
 

RATES OF SERIOUS ADVERSE REACTIONS OF INTEREST WERE COMPARABLE BETWEEN OTEZLA AND PLACEBO1,2

serious adverse reactions were comparable between otezla and a placebo
a

Exposure-adjusted incidence rate/100 patient-years is 100 times the number (n) of patients reporting the event divided by patient-years (up to the first event start date for patients reporting the event).

b

Patients with a history of active or incompletely treated TB were excluded from the trials. The trials included 32 patients with a history of fully treated TB, a positive PPD or QuantiFERON®, or a history of receiving preventive medication for TB.

TB, tuberculosis.

References: 1. Mease PJ, Gladman DD, Gomex-Reino JJ, et al. Long-term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2. Data on file, Celgene Corporation.


Select an e-mail client to share

close x